Trial Profile

Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
Focus Therapeutic Use
Acronyms TRITICC

Most Recent Events

26 Mar 2024 Status changed from active, no longer recruiting to completed.
08 Mar 2024 The trial has been completed (End Date: 07 Jan 2023), according to European Clinical Trials Database record.
26 Feb 2024 Planned End Date changed from 1 Apr 2024 to 1 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com